Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Evaluation Of Soluble Mesothelin-related Peptide As A Diagnostic Marker Of Malignant Pleural Mesothelioma Effusions: Its Contribution To Cytology

P. Canessa, M. C. Franceschini, P. Ferro, E. Battolla, P. Dessanti, C. Manta, M. Sivori, R. Pezzi, V. Fontana, F. Fedeli, M. Pistillo, Silvio Roncella
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. Comparison with cytology in MPM-PE was also performed. We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology. We concluded that SMRP test may be incorporated into clinical practice of PE from patients suspicious for MPM.
This paper references
Clinical Significance Of Pleural Effusion Mesothelin In Malignant Pleural Mesothelioma
S. Yamada (2012)
Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
A Cristaudo (2007)
The Statistical Evaluation of Medical Tests for Classification and Prediction
M. Pepe (2003)
Malignant pleural effusion , current and evolving approaches for its diagnosis andmanagement
S Neragi-Miandoab (2006)
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
Biomarkers for Malignant Pleural Mesothelioma
L. Greillier (2012)
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
Il registro nazionale dei mesoteliomi: risultati, interpretazione, commento ai dati. Il registro Nazionale dei Mesoteliomi. Istituto Superiore per la prevenzione e la sicurezza del la
A Marinaccio (2001)
The undiagnosed pleural effusion.
R. Light (2006)
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
Malignant pleural effusion, current and evolving approaches for its diagnosis and management.
S. Neragi-Miandoab (2006)
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
B. Grigoriu (2009)
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
The diagnostic odds ratio: a single indicator of test performance.
A. S. Glas (2003)
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
Diagnosis and Origin Determination of Malignant Pleural Effusions Through the Use of the Breast Cancer Marker Human Mammaglobin
S. Roncella (2010)
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma
A Scherpereel (2006)
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
C. Alemán (2009)
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
Biomarkers for malignant pleural mesothelioma: current status.
L. Greillier (2008)
ReNaM Working Group. Il registro nazionale dei mesoteliomi: risultati, interpretazione, commento ai dati
A Marinaccio (2001)
Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002).
V. Gennaro (2005)
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
E. Rakha (2010)

This paper is referenced by
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma
Ruiyue Gao (2019)
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
R. Filiberti (2013)
Development of more precise and efficient antibodies for cancer targeting : membrane associated form specific anti-mesothelin antibodies and CAR as an example
K. Asgarov (2016)
A new anti-mesothelin antibody targets selectively the membrane-associated form
K. Asgarov (2017)
Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos
H. Matsuzaki (2013)
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report
P. Canessa (2013)
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
Rosa FilibertiStefano (2013)
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
Takehiro Otoshi (2017)
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
Diagnosis of Pleural Effusions
J. M. Porcel (2013)
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
L. Cortes-Dericks (2017)
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report
Pier Aldo (2013)
Fibulin-3 as biomarker of malignant mesothelioma.
C. Ledda (2019)
Patient-Derived Organotypic Tumor Spheroids Facilitate Precision Medicine Advances in Therapeutic Screening for Malignant Pleural Mesothelioma
Dalia Larios Chavez (2019)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
III Italian Consensus Conference on Malignant Mesothelioma of the Pleura. Epidemiology, Public Health and Occupational Medicine related issues.
C. Magnani (2015)
Semantic Scholar Logo Some data provided by SemanticScholar